+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Active Pharmaceutical Ingredients Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • ID: 4752335
  • Report
  • Region: Global
  • 151 pages
  • IMARC Group
1 of 3

FEATURED COMPANIES

  • Abbvie Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • ELI Lilly Company
  • GlaxoSmithKline
  • Merck & Co. Inc.
  • MORE
The global active pharmaceutical ingredients market was worth US$ 176.3 Billion in 2018. Active pharmaceutical ingredient (API), is the term that is used to refer to the biologically active component of a drug (e.g. tablet, capsule). A drug is usually composed of several components. The API represents the primary ingredient. Other ingredients are commonly known as "excipients. Sometimes a drug can contain several APIs and its effect on a patient depends on the dosage prescribed and can vary from person to person. In combination therapies, two or more than two active ingredients are used to treat different symptoms in different ways. Stringent quality control is a mandate when it comes to the manufacturing of drugs as the API represents the main component considered while making the prescription.

Pharmaceutical manufacturing occurs in two general steps. In the first step, manufacturers convert raw materials into APIs. The second step involves creating the final formulation by mixing APIs and excipients into tablets, capsules, solutions, etc. and finally packaging the drug for the end users. Manufacturers either sell APIs in the open market (also known as the merchant market) or use them as inputs to make their final formulations. The global API market is extremely competitive with a number of large and small manufacturers. Firms that engage in API manufacturing generally specialize and target their manufacturing based on a combination of the firms in-house skills and market opportunities. Catalyzed by lower costs, API manufacturing has gradually been shifting from the historical leaders in Western countries to manufacturers based in India and China.

The global demand of APIs is currently exhibiting strong growth. One of the major drivers of this market is the rising number of blockbuster patent expiries creating a significant opportunity for generic APIs. Moreover, there has been a strong demand for APIs for biologicals. The global market for biologicals is currently exhibiting strong growth catalyzed by their high potency and ability to treat diseases beyond the scope of small molecule drugs. This is creating a strong demand for APIs for branded biological drugs and their biosimilar versions. Other factors catalyzing the global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 247.2 Billion by 2024, exhibiting a CAGR of 5.8% during 2019-2024.

Market Summary:

Based on the drug type, the market has been segmented as innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients.

Based on the type of manufacturer, the market has been segmented as captive manufacturers and merchant API manufacturers.

Based on the type of synthesis, the market has been segmented as synthetic active pharmaceutical ingredients and biotech active pharmaceutical ingredients.

Based on the therapeutic application, the market has been segmented as oncology, cardiovascular disease, diabetes, central nervous system and neurological disorders, endocrinology and others.

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

The competitive landscape of the market has also been examined with some of the key players being Pfizer, Inc., Novartis International AG, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., ELI Lilly and Company, GlaxoSmithKline, Merck & Co., Inc. and Abbvie Inc.
Key Questions Answered in This Report:
  • How has the global active pharmaceutical ingredients market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the global active pharmaceutical ingredients industry?
  • What is the breakup of the global active pharmaceutical ingredients market on the basis of drug type?
  • What is the breakup of the global active pharmaceutical ingredients market on the basis of type of manufacturer?
  • What is the breakup of the global active pharmaceutical ingredients market on the basis of synthesis?
  • What is the breakup of the global active pharmaceutical ingredients market on the basis of therapeutic application?
  • What are the various stages in the value chain of the global active pharmaceutical ingredients market?
  • What are the key driving factors and challenges in the global active pharmaceutical ingredients market?
  • What is the structure of the global active pharmaceutical ingredients market and who are the key players?
  • What is the degree of competition in the global active pharmaceutical ingredients market?
  • How are active pharmaceutical ingredients manufactured?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbvie Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • ELI Lilly Company
  • GlaxoSmithKline
  • Merck & Co. Inc.
  • MORE
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Active Pharmaceutical Ingredients Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Drug Type
5.4 Market Breakup by Type of Manufacturer
5.5 Market Breakup by Type of Synthesis
5.6 Market Breakup by Therapeutic Application
5.7 Market Breakup by Region
5.8 Market Forecast
5.9 SWOT Analysis
5.9.1 Overview
5.9.2 Strengths
5.9.3 Weaknesses
5.9.4 Opportunities
5.9.5 Threats
5.10 Value Chain Analysis
5.11 Porters Five Forces Analysis
5.11.1 Overview
5.11.2 Bargaining Power of Buyers
5.11.3 Bargaining Power of Suppliers
5.11.4 Degree of Competition
5.11.5 Threat of New Entrants
5.11.6 Threat of Substitutes
5.12 Price Analysis
5.12.1 Price Indicators
5.12.2 Price Structure
5.12.3 Margin Analysis

6 Market Breakup by Drug Type
6.1 Innovative Active Pharmaceutical Ingredients
6.2 Generic Active Pharmaceutical Ingredients

7 Market Breakup by Type of Manufacturer
7.1 Captive Manufacturers
7.2 Merchant API Manufacturers
7.2.1 Innovative Merchant API Manufacturers
7.2.2 Generic Merchant API Manufacturers

8 Market Breakup by Type of Synthesis
8.1 Synthetic Active Pharmaceutical Ingredients
8.1.1 Market Breakup by Type
8.1.1.1 Innovative Synthetic APIs
8.1.1.2 Generic Synthetic APIs
8.2 Biotech Active Pharmaceutical Ingredients
8.2.1 Market Breakup by Type
8.2.1.1 Innovative Biotech APIs
8.2.1.2 Biosimilars
8.2.2 Market Breakup By Product
8.2.2.1 Monoclonal Antibodies
8.2.2.2 Vaccines
8.2.2.3 Cytokines
8.2.2.4 Fusion Proteins
8.2.2.5 Therapeutic Enzymes
8.2.2.6 Blood Factors
8.2.3 Market Breakup By Expression System
8.2.3.1 Mammalian Expression Systems
8.2.3.2 Microbial Expression Systems
8.2.3.3 Yeast Expression Systems
8.2.3.4 Plant Expression Systems
8.2.3.5 Insect Expression Systems

9 Market Breakup by Therapeutic Application
9.1 Oncology
9.2 Cardiovascular Disease
9.3 Diabetes
9.4 Central Nervous System and Neurological Disorders
9.5 Endocrinology
9.6 Others

10 Market Breakup by Region
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Middle East and Africa
10.5 Latin America

11 Manufacturing Process
11.1 Product Overview
11.2 Raw Material Requirements
11.3 Manufacturing Process
11.4 Key Success and Risk Factors

12 Competitive Landscape
12.1 Market Structure
12.2 Key Players
12.3 Profiles of Key Players
12.3.1 Pfizer, Inc.
12.3.2 Novartis International AG
12.3.3 Sanofi
12.3.4 Boehringer Ingelheim
12.3.5 Bristol-Myers Squibb
12.3.6 Teva Pharmaceutical Industries Ltd.
12.3.7 ELI Lilly and Company
12.3.8 GlaxoSmithKline
12.3.9 Merck & Co., Inc.
12.3.10 Abbvie Inc.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Teva Pharmaceutical Industries Ltd.
  • ELI Lilly Company
  • GlaxoSmithKline
  • Merck & Co. Inc.
  • Abbvie Inc.
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4752335
Adroll
adroll